Krystal Biotech, Inc. KRYS Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s weighted average exercise price of outstanding options?
- Krystal Biotech, Inc. (KRYS) reported weighted average exercise price of outstanding options of $124.76 in Q1 2026.
- How has Krystal Biotech, Inc.'s weighted average exercise price of outstanding options changed year-over-year?
- Krystal Biotech, Inc.'s weighted average exercise price of outstanding options increased by 34.2% year-over-year, from $92.94 to $124.76.
- What is the long-term trend for Krystal Biotech, Inc.'s weighted average exercise price of outstanding options?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s weighted average exercise price of outstanding options has grown at a 19.8% compound annual growth rate (CAGR), from $40.31 to $99.45.